Clinical trial
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in…
NCT00122837 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00122837 |
|---|---|
| Title | A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder |
| Official title | A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Boehringer Ingelheim Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anxiety Disorder |
| Intervention type | Drug |
| Interventions | Duloxetine, venlafaxine, placebo |
| Enrollment | 560 |
| Start date | Apr 1, 2005 |
| Completion | Jan 1, 2007 |
| First posted | Jul 22, 2005 |
| Last update posted | Oct 18, 2007 |
| Countries | Argentina, Australia, Belgium, Canada, Mexico, Russia, Taiwan, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: